Liver transplantation Surgery
Conditions
Interventions
This is a study of isolated livers undergoing normothermic perfusion ex situ (ex vivo). There are additional readouts for some groups)
Study groups (n=6 to 10) will undergo incremental changes before
Sponsors
University of Cambridge
Cambridge University Hospitals NHS Foundation Trust
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Aged =18 years 2. Requiring a liver transplant
Exclusion criteria
Exclusion criteria: 1. Lack of consent 2. Inability to comprehend the information
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Transcriptomic profile measured using liver biopsies collected into RNA Later before and after 4 hours and at the end of liver perfusion and after reperfusion in the recipient | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Transcriptomic signature measured using DESeq on biopsies of the liver taken pre-perfusion and after 4h, and at the end of perfusion and following reperfusion 2. Post transplant function: 2.1. Post reperfusion syndrome measured using mean blood pressure measured using an invasive arterial pressure monitor recording for the five minutes before and after reperfusion of the liver 2.2. Early allograft function measured using the model for early allograft function score which looks at recipient biochemical and haematological variables over the first 3 days post transplant 2.3. Early allograft function measured using L-GraFT7 score which looks at recipient biochemical and haematological variables over the first 7 days post transplant 2.4. Early allograft function measured using Olthoff score which looks at recipient biochemical and haematological variables over the first 7 days post transplant 2.5. Incidence of anastomotic and non-anastomotic structures in DCD livers measured using MRCP in the first 6 months post transplant 2.6. Peak creatinine d1-7 measured using serum creatinine measurements at baseline and the first 7 days post transplant 3. Perfusate chemistry: 3.1. TBARS measured using perfusate from the liver machine taken after 30mins and 4 hours of perfusion will be measured using a commercial kit 3.2. HMGB-1 measured using perfusate from the liver machine taken after 30mins and 4 hours of perfusion will be measured using a commercial kit 3.3. Hyaluronic acid levels measured using perfusate from the liver machine taken after 30mins and 4 hours of perfusion will be measured using a commercial kit 3.4. Uric acid measured using the Piccolo Express near patient analyser at 1, 2 and 4 hours 3.5. D-dimer concentration (thrombolysis group) measured on perfusate taken after 30mins and 4 hours of perfusion using a commercial assay kit Early allograft function and cholangiopathy are based on tests in the recipient post transplant; one post transplant biopsy for transc | — |
Countries
England, United Kingdom
Contacts
Public ContactChris Watson
Outcome results
None listed